Reckitt Benckiser To Commence All-Cash Tender Offer To Acquire Schiff Nutrition For $42 Per Share

    Reckitt Benckiser To Commence All-Cash Tender Offer To Acquire Schiff
                         Nutrition For $42 Per Share

  PR Newswire

  SLOUGH, England, Nov. 15, 2012

-- Acquisition to Provide Reckitt Benckiser a Significant Opportunity to Enter
Large and Growing Vitamins, Minerals and Supplements Market

-- Cash Offer Represents 23.5% Percent Premium to Announced Bayer Group
Transaction And Tender Offer Can Close by Year-End

SLOUGH, England, Nov. 15, 2012 /PRNewswire/ -- Reckitt Benckiser Group PLC
("Reckitt Benckiser") (LSE: RBL) today announced that it will commence a
tender offer tomorrow, November 16, 2012 to acquire all of the outstanding
shares of Schiff Nutrition International, Inc. ("Schiff") (NYSE: SHF), a
leading provider of branded vitamins, nutrition supplements and nutrition bars
in the United States and elsewhere, for $42.00 per share in cash valuing
Schiff at approximately $1.4 billion. Reckitt Benckiser's offer is not
dependent on financing as the purchase will be funded from existing
facilities.

Reckitt Benckiser's offer represents a premium of 23.5 percent over the $34.00
per share transaction announced on October 30, 2012 by Bayer HealthCare LLC
("Bayer") and Schiff. Reckitt Benckiser is confident that it can close the
tender offer before the end of calendar year 2012, provided it is permitted in
short order to complete limited confirmatory due diligence.

Schiff's vitamin, minerals and supplements (VMS) product portfolio includes a
number of market leading brands in the specialist product category in the USA,
including MegaRed®, number 1 in the healthy heart segment, Move Free® the
number 2 in joint care, Airborne® the number 2 in immune support, and Schiff
Vitamins®.

Rakesh Kapoor, Reckitt Benckiser Chief Executive Officer, said, "For Reckitt
Benckiser, this acquisition would provide a powerful entryway into the large
and rapidly growing $30 billion global VMS market. This market would be the
largest consumer health care sector in which we operate. It is an ideal
addition to Reckitt Benckiser's new strategic focus in global health and
hygiene, and would give us immediate scale in VMS in the USA. It also plays
well to our consumer marketing, innovation and go to market capabilities."

He continued, "We are confident that the VMS market drivers, notably changing
demographics and increased awareness of the health and wellness benefits of
VMS products, will provide significant long-term growth potential in what is
currently a very fragmented market."

"We firmly believe that our entrepreneurial and consumer-focused mindset, our
infrastructure, speed and scale, combined with Schiff's leading brand
portfolio, will generate sustained value for our shareholders," he said.

Based on the financial information disclosure dated October 29, 2012 and made
public in its 14C SEC filing on November 5, 2012, Schiff expects to achieve
net sales of $385 million and proforma EBITDA of $84.6 million for the fiscal
year ending May 31, 2013. Reckitt Benckiser expects the transaction will
result in significant synergies and that it would be immediately accretive to
earnings on an adjusted basis.

Reckitt Benckiser sees no reason why this tender offer could not close before
year end, assuming prompt due diligence, and it will be prepared to sign a
merger agreement substantially similar to the one Schiff currently has with
Bayer. Reckitt Benckiser looks forward to engaging with Schiff's Board and is
confident that they will recognize it as a superior proposal.

The Offer to Purchase, Letter of Transmittal and other offering documents will
be filed tomorrow, November 16, 2012, with the Securities and Exchange
Commission. Investors and stockholders of Schiff may obtain copies of all of
the offering documents free of charge at the Securities and Exchange
Commission's website ( www.sec.gov ). Reckitt Benckiser's offer will be
subject to Schiff and its controlling stockholders terminating their merger
and related agreements with Bayer and entering into definitive agreements with
Reckitt Benckiser, and to other customary conditions, including the tender of
a majority in voting power of Schiff shares of common stock, all of which will
be set forth in the offering documents to be filed. Reckitt Benckiser believes
it can promptly obtain any necessary regulatory approvals, including approval
under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act).

Morgan Stanley & Co. Limited is acting as exclusive financial adviser to
Reckitt Benckiser and no one else in connection with the matters described in
this announcement. In connection with such matters, Morgan Stanley & Co.
Limited, its affiliates and their respective directors, officers, employees
and agents will not regard any other person as their client, nor will they be
responsible to any other person for providing the protections afforded to
their clients or for providing advice in relation to the transaction, the
contents of this announcement or any other matter referred to herein.

Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as Reckitt Benckiser's
legal advisor.

Conference Call Information Reckitt Benckiser will conduct a conference call
with financial analysts and investors on November 16, 2012 at 07:30 Greenwich
Mean Time (02:30 USA Eastern Standard Time) to discuss the offer.

Participants can access the call by dialling :

Participant Dial-In Numbers:
United Kingdom               08006940257
Std International Dial-In:   +44 (0) 1452 555566
United Kingdom, LocalCall    08444933800

Conference ID: 72072243

A replay of the conference call can be accessed via :

UK National Call Dial-In:  08717000145
UK LocalCall Dial-In :     08452455205
Std International Dial-In: +44 (0)1452550000

Conference ID: 72072243

Available from: 16 Nov 201208:30 GMT to 15 Dec 201208:30 GMT

A recording of the conference call will be available on http://www.rb.com/

About Reckitt Benckiser Reckitt Benckiser (RB) is a global consumer goods
leader in health, hygiene and home, listed on the London Stock Exchange (LSE).
With a purpose of delivering innovative solutions for healthier lives and
happier homes, RB is in the top 25 of companies listed on the LSE. Since 2000
net revenues have more than doubled and the market cap has quadrupled. Today
it is the global No 1 or No 2 in the majority of its fast-growing categories,
driven by an exceptional rate of innovation. Its health, hygiene and home
portfolio is led by 19 global Powerbrands including Nurofen, Strepsils
Gaviscon, Mucinex, Durex, Scholl, Lysol, Dettol, Clearasil, Veet, Harpic,
Bang, Mortein, Finish, Vanish, Woolite, Calgon, Airwick, and French's, and
they account for 70% of net revenue.

RB people and its culture are at the heart of the company's success. They have
an intense drive for achievement and a desire to outperform wherever they
focus, including in CSR where the company has reduced its carbon footprint by
20% in 5 years and is now targeting to deliver a 1/3 reduction in water use,
1/3 further reduction in carbon and have 1/3 of its net revenue coming from
more sustainable products by 2020. It is also the Save the Children charity's
largest FMCG global partner.

The company has operations in over 60 countries, with headquarters in the UK,
Singapore, Dubai and Amsterdam, and sales in almost 200 countries. The Company
employs approximately 32,000 people worldwide.

For more information visit http://www.rb.com/

Forward-Looking Statements Statements herein regarding the proposed
transaction between Reckitt Benckiser and Schiff, future financial and
operating results and any other statements about future expectations
constitute "forward looking statements." These forward looking statements may
be identified by words such as "believe," "expects," "anticipates,"
"projects," "intends," "should," "estimates" or similar expressions. Such
statements are based upon current beliefs and expectations and are subject to
significant risks and uncertainties. There are a number of important factors
that could cause actual results or events to differ materially from those
indicated by such forward looking statements. We believe these forward-looking
statements are reasonable; however, undue reliance should not be placed on any
forward-looking statements, which are based on current expectations. All
written and oral forward-looking statements attributable to us or persons
acting on our behalf are qualified in their entirety by these cautionary
statements. Further, forward-looking statements speak only as of the date they
are made, and we undertake no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of unanticipated
events or changes to future operating results over time unless required by
law.

Important Additional Information This document is for informational purposes
only and is not an offer to buy or the solicitation of an offer to sell any
securities. The solicitation and offer to buy the common stock of Schiff will
only be made pursuant to an offer to purchase and related materials that the
acquirer intends to file with the Securities and Exchange Commission.
Stockholders should read these materials carefully when they become available
because they will contain important information, including the terms and
conditions of the offer. Stockholders will be able to obtain the offer to
purchase and related materials with respect to the tender offer free of charge
at the SEC's website at www.sec.gov or from MacKenzie Partners, Inc., Reckitt
Benckiser's Information Agent, at 800-322-2885 (toll-free) or at
+1-212-929-5500 (call collect).

Investor & Analyst Contacts: Reckitt Benckiser (RB) United Kingdom Richard
JoyceDirector, Investor Relations +44 1753 217800

Media Contacts: United States Sard Verbinnen & Co Jim Barron/Jared Levy+1
(212) 687-8080

United Kingdom Reckitt Benckiser (RB) Andraea Dawson-ShepherdSVP, Global
Corporate Communication & Affairs +44 1753 446447

Website: http://www.rb.com
 
Press spacebar to pause and continue. Press esc to stop.